<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916604</url>
  </required_header>
  <id_info>
    <org_study_id>D1020C00004</org_study_id>
    <nct_id>NCT00916604</nct_id>
  </id_info>
  <brief_title>To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients</brief_title>
  <acronym>JMAD</acronym>
  <official_title>A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple
      repeated oral doses in Japanese patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic variables (AUC, Cmax, tmax, t½, CL/F, Ae and CLR).</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide).</measure>
    <time_frame>Blood samples taken repeatedly during 24 hours on study day sessions</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oral suspension given to 3 groups (2 on placebo in each group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1656</intervention_name>
    <description>Three increasing dose-steps with oral suspension, 8 days treatment</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral suspension, 8 days treatment</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female non-childbearing potential Japanese T2DM patients, 30-75 years.

          -  A body mass index (BMI) of 19 to 27 kg/m2.

          -  Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two
             oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment
             within 3 months prior to enrollment.

        Exclusion Criteria:

          -  Renal dysfunction GFR &lt; 60 mL/min.

          -  Systolic pressure (SBP) &gt; 160 mmHg or diastolic pressure (DBP) &gt; 95 mmHg

          -  Clinically significant illness or clinically relevant trauma, as judged by the
             investigator, within two weeks before the first administration of the IP.

          -  History of ischemic heart disease, stroke, transient ischemic attack or symptomatic
             peripheral vascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klas Malmberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Mölndal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Takashi Eto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PS Clinic, Fukuoka, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitsuyasu Hokamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HONJO CLINIC II, Tokyo, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>November 2, 2009</last_update_submitted>
  <last_update_submitted_qc>November 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Klas Malmberg, MD, PhD, Prof, Medical Science Director</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>AZD1656</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Multiple ascending doses</keyword>
  <keyword>Japanese</keyword>
  <keyword>T2DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

